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Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of
conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising
from autologous or allogeneic transplants. Many cells administered show transient presence for a few
days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered
as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft
versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some
with early benefits to patients.Introduction
Stem cell therapies have been expected to bring substantial
benefit to patients suffering a wide range of diseases and in-
juries. It was expected that the benefits of bone marrow trans-
plants for patients needing reconstruction of their hematopoietic
and immune systems would apply to stem cell transplants of
other cell types, and optimism has been high for the utilization
of pluripotent stem cell types (embryonic stem cells [ESCs]
and induced pluripotent stem cells [iPSCs]) for a variety of appli-
cations.
For the entire area of cell therapies in 2014, 70% of trials were
sponsored by academic institutions (public funding) and 30% by
companies (the private sector) (Bersenev, 2015). A combination
of public and private funding was strongly advocated in the fund-
ing of translation and clinical stem cell trials for sustained capac-
ity by the Californian Institute for Regenerative Medicine (CIRM)
(Trounson et al., 2010). There is a very significant investment
overall in the field of stem cell clinical trials that deserves moni-
toring and evaluation. Successful new therapies come at a
considerable cost that cannot easily be sustained without evalu-
ation and guidance. We have explored the clinical trials in which
data have now been published and which the general and sci-
ence community are anxious to follow given the investment of
research resources and finance. These trial outcomes will
deserve continuous evaluation to enable an understanding of
the extended timeframes involved in realizing successful prod-
ucts and an understanding of the collateral losses for potential
products that are unable to meet the demands of the regulatory
system and clinical efficacy of therapy.
Since previous reviews of stem cells in clinical trials (Ratcliffe
et al., 2013; Trounson et al., 2011), there has been a continuing
expansion in the number and type of stem cells under study.
We examined the reports of clinical trials in the NIH and Euro-
pean databases to classify them by stem cell type and disease
application. We searched for clinical trial data published in
peer-reviewed journals and sought out publically available infor-
mation on trials performed by companies. Data for some studies
are regularly published, but for many trials data are unavailable
or not easily accessed. Given the relative immaturity of the cell
therapy field, it is important to know the outcomes of early clin-ical trials to help guide others in the processes. The overall
impression is that considerable investment has been made in
preclinical research and clinical trials, but as yet there is only a
modicum of success being achieved. However, clinical reports
will continue to evolve and general trends will emerge. It is clear
that limbal stem cells have matured, neural stem cells show
considerable promise for regenerative repair, pluripotent stem
cells have an abundant potential in regenerative medicine, and
mesenchymal stem cells (MSCs) are numerically the most
favored cell type presently under clinical trial. These studies
attract a lot of attention for commentary in the press and patient
expectations of substantial benefits. We also considered
placental-derived stem cells that are frequently MSC-like and
endothelial stem or progenitor cells because of their close
relationship to perivascular repair necessary in regenerative
medicine.
The prevalence of cell therapies for injury and disease of the
eye is a notable trend. This progress is a result of a few factors,
including the relatively small numbers of cells required, easy
accessibility for surgery, and straightforward assessment and
visualization of grafts. There also appears to be some immune
privilege for allogeneic transplants to the eye. Furthermore,
one eye can be used as a control when cell therapy is applied
to the other eye because disease is generally bilateral. It is also
relatively easy to differentiate pluripotent cells into cell types
needed for regenerative purposes in the eye. Consequently
numerous types of cells have been used in clinical trials for eye
disease and injury.
The present Review has been confined to published reports of
stem cell clinical trials and excludes the very substantial litera-
ture on hematopoietic (blood) stem cells and associated gene
therapies and cancer cell therapies. The latter has dramatically
expanded with the success of chimeric antigen receptor tech-
nology but presently doesn’t involve stem cells. The published
data on registered clinical trials involving stem cells other than
hematopoietic stem cells is relatively lean and we examine and
discuss the safety and efficacy data that have been provided
in publications or company reports. In this young field with
considerable promise, there are exciting prospects for many
different stem cell therapies that are arising from the early trialsCell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc. 11
Table 1. ESC Trials
Trial Sponsor (Location) Disease Target Cell Therapy No. Patients Phase
Chabiotech Co. Ltd. (S. Korea) macular degeneration human-ESC-derived RPE 12 phase I/II
Ocata Therapeutics (MA, USA) Stargardt’s macular dystrophy human-ESC-derived RPE 16 phase I/II
macular degeneration human-ESC-derived RPE 16 phase I/II
myopic macular degeneration human-ESC-derived RPE unknown phase I/II
Pfizer (UK) macular degeneration human-ESC-derived RPE 10 phase I
Cell Cure Neurosciences Ltd. (Israel) macular degeneration human-ESC-derived RPE 15 phase I/II
ViaCyte (CA, USA) type I diabetes mellitus human-ESC-derived pancreatic
endoderm cell
40 phase I/II
Assistance Publique-Hopitaux de Paris
(France)
heart failure human-ESC-derived CD15+ Isl-1+
progenitors
6 phase I
International Stem Cell Corp. (Australia) Parkinson’s disease human parthenogenetic-derived neural
stem cells
unknown phase I/II




Reviewas well as some disappointments that are tempering the opti-
mism for new cures occurring rapidly across a large spectrum
of disease and injury.
Pluripotent Stem Cells
Both ESCs and iPSCs are making their way into clinical trials
(Table 1) after considerable optimism for their therapeutic poten-
tial. They are of most interest where functional adult stem cell
types are difficult to access, expand, or derive. It appears that
applications in the eye, pancreas, and various neural degenera-
tive disorders or injuries such as Parkinson’s disease, amyotro-
phic lateral sclerosis (ALS), and spinal cord injury are leading
candidates for pluripotent stem cell-based cell therapy.
The original Geron Inc. clinical trial of human ESC (hESC)-
derived oligodendrocyte progenitors for the treatment of spinal
cord injury, the first of its kind to use ESCs, was terminated
when the company decided to discontinue their cell therapy pro-
gram to concentrate on cancer treatments. They treated five
patients without any adverse findings with a dose below that ex-
pected to show any efficacy. The estimated costs of the preclin-
ical studies (US$200 million) (Keirstead, 2012, Spinal cord injury:
what are the barriers to cure? Bedford Center Workshop) were
very high because of the pioneering data required to show safety
against teratoma formation and animal model efficacy needed
for the first in human studies of hESCs. The actual clinical trials
were also very costly because of the number of trial sites, training
for the transplant procedure, and cell manufacturing. The study
is now continuing under the direction of Asterius Biotherapeutics
who have registered a dose escalation phase I safety trial with
the FDA, using the same hESC-derived oligodendrocyte progen-
itor cells administered 1–2 weeks after spinal cord injury.
Preliminary results have been reported by the company Ocata
Therapeutics (formally ACT) on clinical safety trials for the use of
retinal pigmented epithelial cells (RPEs) derived from hESCs for
dry macular degeneration and Stargardt’s macular dystrophy
(Schwartz et al., 2012, 2015). They were able to derive RPEs
that were 99% pure from hESCs. There were 9 patients with
macular degeneration and 9 patients with Stargardt’s disease
in dose cohorts of 50,000, 100,000, and 150,000 cells adminis-
tered to one eye of each patient. The only adverse events were12 Cell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc.associated with surgery and immunosuppression. Visual acuity
improved in 10 treated eyes, was stable in 7 eyes, and decreased
in 1 eye over 22 months. Patches of regenerated retinal epithe-
lium were observed in 72% of the patients although the spread
was variable and incomplete, suggesting that improvements
could be made to the methodology to achieve greater RPE
monolayer coverage of the macula. Other clinical studies are
emerging on macular degeneration, which include studies in
the UK and in California, where ESC-derived RPEs are grown
as a monolayer on ultra-thin scaffolds and inserted under the
photoreceptor cells to cover the entire macula. There is also a
report of one Japanese patient who received a transplant of a
sheet of iPSC-derived RPE (Cyranoski, 2014). This is the first in
human study that may be the leader in many other applications
of iPSC derivatives. While it might be expected that iPSCs will
be used as autologous therapies, there is a strong movement
for their use as allogeneic transplants or as partially compatible
HLA haplotyped derivatives (Turner et al., 2013).
Reports of progress for other indications undergoing treat-
ment with pluripotent stem cells are not available as yet. This in-
cludes the use of insulin-producing b Islet cells contained in a
subcutaneous capsule to prevent cell-mediated autoimmunity
in patients with type I diabetes (Schulz et al., 2012). This study
is an open label dose-escalating phase I/II trial involving 40 pa-
tients. The first patient received a transplant in November 2014
of two subcutaneous capsules of b Islet progenitors differenti-
ated from ESCs. This study is being conducted by the company
ViaCyte in California and the results will be interesting because
there will be a functional readout of the transplanted cells con-
trolling diabetes. In the Viacyte studies the final stages of matu-
ration to glucose-responsive insulin-producing cells needs to be
done in vivo. More recently two research groups reported the
apparent complete maturation of cells into b Islet cells in vitro,
but at this stage it is not known if this may benefit their efficacy
when used in clinical trials or not (Kushner et al., 2014).
There was also a recent announcement by International
Stem Cell Corporation that they will begin clinical studies in
Australia in 2015. The study will use parthenogenetic ESC-
derived neural cells for the treatment of Parkinson’s disease
(ISCO, 2015). The main concern for this study may be how well
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nergic neurons, given the potential for associated dyskinesia
from the contamination of serotoninergic neurons (CIRM,
2013). Attempts to replicate the positive outcomes from human
fetal ventral mesencephalon tissue transplants, using pluripotent
stem cells, are a major focus that has challenged researchers to
derive the nigral A9 dopaminergic neurons that are able to func-
tionally recover the 6-OHDA animal model of Parkinson’s dis-
ease when grafted at a dose equivalent to that used for fetal
VM, as recently shown by Grealish et al. (2014). These chal-
lenges have been summarized by Barker (2014) in discussing
the consortia involved in fetal brain transplants and the newly
formed Parkinson’s Global Force (Abbott, 2014) that is guiding
researchers to optimize their cell characterization and the patient
subgroups likely to respond to therapeutic transplants. There is
concern that clinical trials based on less robust criteriamay again
set back the clinical progress toward successful therapy for this
disease.
Limbal Stem Cells
Limbal stem cell transplants have been used very successfully to
restore functional corneal epithelium that is transparent and self-
renewing in patients who have corneal destruction, usually due
to burns (Rama et al., 2010). The limbal cells are autologous
transplants obtained from the limbus, providing even a tiny
part in either of the patient’s two eyes has been spared from
injury, and they are expanded in culture on fibrin (Rama et al.,
2010) or human amniotic membrane (Kolli et al., 2010) that pre-
serves and enables expansion of the holoclone cells. Allogeneic
limbal cells do not persist long-term after transplantation (Pelle-
grini and De Luca, 2014).
iPSC derivation of the limbal lineage may eventually provide a
therapeutic source of limbal cells for patients for whom complete
bilateral destruction or loss or absence of the limbus has
occurred. Recent advances in the identification of key regulatory
genes in limbal development, differentiation, and expansion are
likely to accelerate this therapeutic opportunity (Pellegrini et al.,
2014). In the meantime, transplantation of in vitro cultured non-
ocular autologous oral mucosal epithelium has been used in
patients with bilateral limbal cell deficiency, particularly for acute
chemical burns. This procedure can give satisfactory results
(Burillon et al., 2012; Chen et al., 2009) and provide adequate
re-epithelialization and stabilization of the surface of the cornea
if the cultured autologous thin sheets (with a few cells’ worth of
thickness) of oral mucosal epithelium are lifted with temperature
sensitive cell sheet-lifting technology that preserves the cultured
cell-cell junctions and an intact basement membrane for trans-
plantation (Burillon et al., 2012). This method appears to prevent
the vascularization and loss of corneal opacity previously asso-
ciated with oral mucosal transplants that often had multiple
epithelial layers of stratification and numerous mucosal cell
structures (Chen et al., 2009).
Cadaveric limbal tissue can be preserved with intact structure
at 4C for up to 8 days by airlift culture (which is a method
wherein the stromal component of the cornea is submerged in
liquid culturemedium and the epithelium is exposed to air for cul-
ture or cold preservation) and used for allogeneic transplants
that provide complete corneal re-epithelialization for at least
1 month (Li et al., 2013). This result suggests allogeneic limbalstem cell therapies are steadily progressing. However, a recent
study on allografts in Aniridia and Stevens-Johnson Syndrome
that used a defined outcomes set procedure for cultured limbal
cell epithelium transplants for bilateral limbal cell deficiency
showed improvements in epithelial integrity and visual acuity
up to 12 months but then a gradual decline over 3 years (Shortt
et al., 2014). Typically restoration of the corneal epithelium can
now be achieved in the majority (67%) of auto- and allogeneic
transplants for partial and total limbal stem cell deficiency
without easily detectable alteration to visual acuity (Zakaria
et al., 2014).
Neural Stem Cells
Neural stem cell derivatives are in a number of clinical trial appli-
cations (Table 2). The applications are primarily aimed at repair-
ing the damaged central nervous system. The best type of neural
cell for regenerative repair of the central nervous system is still
yet to be determined and may vary according to the disease or
injury. It is generally considered that a neural stem cell is prob-
ably ideal for establishing a stem cell pool for continuous supply
of the desired neuron, astrocyte, or oligodendrocyte. However,
mature neural cells may also be necessary when specific cell
types are needed to achieve normal function. For example, nigral
A9 dopaminergic neurons are needed in Parkinson’s disease. It
can be surprising that a brain neural stem cell can repair loss of
RPE in macular degeneration. Clinical studies will also eventually
determine whether a neural stem cell or oligodendroctye pro-
genitor is best for spinal cord repair.
Studies by the Stem Cells Inc. group have used human fetal-
derived neural stem progenitors, which show lifelong lysosomal
enzyme production, to treat very advanced infantile or late-infan-
tile ceroid lipofuscinosis (Batten’s disease) in children without
any detectable adverse events (Selden et al., 2013). Doses of
1 billion cells into the brain were well tolerated in these patients.
Furthermore, the allogeneic cells showed long-term survival of
the transplanted cells in autopsy 2.5 years later and 1.5 years
after the termination of immunosuppression. Three patients (of
six) are more than 5 years post-transplant. The company has
also treated young patients with the fatal genetic demyelination
condition known as Pelizaeus-Merzbacher disease (PMD)
(Gupta et al., 2012). The neural progenitors were surgically im-
planted into the frontal lobe white matter in four young patients
with an early-onset severe form of PMD and some modest gains
in neurological function were observed in three patients. Cranial
magnetic resonance imaging and MR spectroscopy indicted
that myelination occurred in the site of transplantation when
compared to white matter sites distant to transplantation.
Further progress has been limited because it is difficult to recruit
young patients prior to the exhibition of the advanced disease
phenotype. These studies indicate that it may be possible to
halt the advance of severe genetic disorders by providing neural
stem cell transplants that are vehicles for delivery of the correct
protein.
Perhaps more challenging is the treatment of stroke and other
disorders of the brain and spinal cord. Despite a very large num-
ber of studies in animals using neural, embryonic, mesenchymal,
bone marrow, and cord blood cell types, there appears ‘‘little
evidence that transplanted stem cells or their derivatives can
replace damaged cells, reconstruct neural circuits, or improveCell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc. 13
Table 2. Neural Stem Cell trials
Trial Sponsor (Location) Disease Target Cell Therapy No. Patients Phase
City of Hope
(CA, USA)
recurrent high grade gliomas E. Coli CD-expressing neural stem cells 24 phase 1
recurrent high grade gliomas carboxylesterase-expressing neural
stem cells
53 phase I
Neuralstem Inc. (MD, USA) ALS fetal-derived neural stem cells 18 phase I
ALS fetal-derived neural stem cells 18 phase II
chronic spinal cord injury fetal-derived neural stem cells 4 phase I
ReNeuron Ltd. (UK) stroke human neural stem cells 12 phase I
stroke human neural stem cells 41 phase II
lower limb ischemia human neural stem cells 9 phase I
Stem Cells Inc. (CA, USA) neuronal ceroid lipofuscinosis human CNS stem cells 6 phase I
cervical spinal cord injury human CNS stem cells 50 phase II
macular degeneration human CNS stem cells 15 phase I/II
thoracic spinal cord injury human CNS stem cells 12 phase I/II
Pelizaeus-Merzbacher disease human CNS stem cells 4 phase I
TRANSEURO (UK) Parkinson’s disease fetal-derived dopaminergic cells 40 phase I
Wroclaw Medical University (Poland) spinal cord injury olfactory ensheathing cells, autologous 10 phase I
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company ReNeuron uses immortalized human fetal neural stem
cells for transplantation to stroke patients and has reported no
cell-related or immunological adverse events in a phase I study
of 11 patients in their followup after 12 months (ReNeuron,
2014). These immortalized human neural stem cells do not colo-
nize brain tissue and are a transient population that appears to
have a trophic influence on brain function. While the study was
not designed to measure efficacy, some improvements were
observed in patient spasticity and neurological impairment.
A second phase II trial is underway for the evaluation of the
benefit of these neural stem cell transplants 2–4 months after
stroke, involving a futility study of 41 patients (no controls) in
two separate trial cohorts.
ALS is an adult onset neurodegenerative disease that is a
result of motor neuron degeneration in the cerebral cortex, brain
stem, and spinal cord. A phase I study by the company Neural-
stem for ambulatory and non-ambulatory ALS patients used in-
traspinal injection of 500,000 to 1 million human fetal spinal
cord neural stem cells into in the lumbar and cervical regions
of the spinal cord. This study showed no cell-related adverse
events but little indication of improved survival benefit (Feldman
et al., 2014; Glass et al., 2012; Riley et al., 2012). An ambulatory
phase II study involved multiple cervical injections of 2–8 million
cells or 160 million cells into the lumbar and cervical spinal cord
regions (Thomsen et al., 2014). While preclinical ALS animal
model studies show some efficacy of prolonged survival after
neural cell transplants (Lee et al., 2014a; Thomsen et al., 2014),
significant benefit is still awaited for ALS in human phase II clin-
ical trials.
Neural stem cells are also in clinical trials for spinal cord repair.
The use of adult olfactory nasal ensheathing cells for differentia-
tion into neural progenitors for spinal transplantation (Tabakow
et al., 2013) is complicated by the possible retention of the
unwanted growth of a multicystic mass of mixed nasal cell phe-
notypes (Dlouhy et al., 2014). This has not been the experience14 Cell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc.with transplants of fetal-brain-derived neural stem cell progeni-
tors. The company Stem Cells Inc. has been undertaking a
Phase I/II clinical trial of their fetal neural stem cell progenitors
in 12 chronic stage (ASIA-A and B) patients with T2–T11 injuries
in Switzerland. They received a total dose of 20 million cells in
four injections above and below the site of injury. There have
been no adverse cell-related effects reported in these patients,
and there have been segmental gains in sensory and electro-
physiological response that occur over time. Several patients
progressed from ASIA-A to B (patients with some rectal control)
and some had a return of minor motor control capacity. Patients
are now being recruited for phase II trials in Canada and the USA
involving the more common cervical injuries (StemCells Inc.,
2014).
Based on evidence in animal studies for the capacity of human
neural brain stem cells to protect against retinal degeneration
and maintenance of photoreceptor health (McGill et al. 2012;
Cuenca et al., 2013), the company Stem Cells Inc. has also
used its neural stem cells for treating human blindness due to
dry macular degeneration. In a phase I/II dose escalation study
(200,000 to 1 million cells), they showed stable and improved
visual acuity in subjects at 6 and 12 months after subretinal
injection of neural stem cells with reduced growth of retinal
geographic atrophy of the treated eye verses the non-treated
eye (StemCells Inc., 2015). A phase II proof-of-concept study
is now underway to confirm the maintenance of sight in this
type of patient.
Transformed neural stem cell lines have also been used to
carry a payload of cytotoxic drugs to the site of glioblastoma
tumors in the brain. These studies rely on the homing character-
istics of neural stem cells to tumors (Aboody et al., 2000).
Researchers at the City of Hope, LA have genetically modified
neural stem cells with enzymes that are able to convert prodrugs
administered to patients to highly potent cytotoxins in the local-
ized sites of the tumor (Aboody et al., 2013). The primary clinical
studies have shown conversion of the prodrug flucytosine (5-FC)
Table 3. Placental Stem Cell Trials
Trial Sponsor (Location) Disease Target Cell Therapy No. Patients Phase
Celgene Corporation (NJ, USA) stroke (terminated) human placenta-derived cells 44 phase II
pulmonary sarcoidosis (terminated) human placenta-derived cells 4 phase I
CD human placenta-derived cells 14 phase I
MS human placenta-derived cells phase I
peripheral artery disease human placenta-derived cells 24 phase I
rheumatoid arthritis human placenta-derived cells 26 phase II
Karolinska Institute (Sweden) GVHD decidual stromal cells (MSC-like) 30 phase I/II
hemorrhagic cystitis decidual stromal cells (MSC-like) 12 phase I/II
Prince Charles Hospital/Mater Medical
Research Institute (Australia)
idiopathic pulmonary fibrosis placental mesenchymal stromal cell 8 phase I
New York Medical College (NY, USA) immune disorders human placental-derived stem cells 30 phase I
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the prodrug. A dose escalation study is underway to assess effi-
cacy of this treatment on glioma reduction (Hirmand, 2014). The
group is also exploring the use of engineering carboxyl esterase
into neural stem cells to activate the potent cytotoxin CPT-11 for
destruction of lung and brain cancers (Hong et al., 2013). There
are no data available from these clinical studies as yet.
Endothelial Stem or Progenitor Cells
There are many (>60) clinical trials listed on the NIH clinical trials
website (https://clinicaltrials.gov/) for endothelial stem/progeni-
tor cells, the majority with unknown status. Of the 12 studies of
known status, all are autologous transplants, 11 are phase I/II tri-
als, and 1 is phase II. In these studies the cells are either sourced
from the bone marrow or peripheral blood. Treatments include
transfusion of endothelial progenitor cells in patients with idio-
pathic pulmonary arterial hypertension, where improvements
were observed in walking distance, mean pulmonary artery pres-
sure, pulmonary vascular resistance, and cardiac output (Wang
et al., 2007). They have also been used for refractory angina in
an attempt to foster angiogenesis (Jimenez-Quevedo et al.,
2014). In this trial of 28 patients (19 treated and 9 controls), there
were no adverse cell-related effects (one patient in the treatment
group and one in the control group died) but there was a reduc-
tion in the mean number of angina episodes per month in the
treatment group. Otherwise efficacy parameters were not
different. Some benefit of autologous endothelial cell transplants
was seen in post-mastectomy lymphedema volume, but other
parameters were not different from those of controls (Maldonado
et al., 2011). A number of trials have also been undertaken for
critical limb ischemia, using the autologous CD34+ fraction
(endothelial and hematopoietic stem cells) of granulocyte col-
ony-stimulating factor (GC-SF) mobilized blood cells (Kawamoto
et al., 2009; Kinoshita et al., 2012). These have shown strong
favorable trends in efficacy parameters that encourage further
randomized and controlled phase II trials to protect against
serious disease sequealae. While a genuine therapeutic role for
endothelial progenitor cell transplantation remains highly desir-
able for repair of vascular injury, strong evidence for repair of
the cardiovascular system by endothelial progenitor cells from
human clinical trials remains to be demonstrated (Mitchell
et al., 2015).It is of interest that bone marrow MSCs are being trialed for
critical limb ischemia without endothelial cells with very minor
benefits noted in phase I/II trials (Gupta et al., 2013). Serious
adverse events occurred in both placebo and treatment arms.
Umbilical cord blood MSCs have also been used in phase I
studies without influencing serious events and showing some
very minor improvements in angiographic scores (Yang et al.,
2013). It would be interesting to compare MSCswith and without
endothelial cell combination treatments.
Placental Stem Cells
Cells derived from the human placenta are in clinical trials for a
variety of therapeutic applications (Table 3). A fraction identified
as placental MSCs by its adherence to plastic and expression of
typical cell surface markers has been used to treat patients with
idiopathic pulmonary fibrosis. In a single-center, non-random-
ized, intravenous dose escalation (1–2 million cells/kg) phase I
study, some minor and transient acute adverse effects were
shown and no observable improvement in any parameters
relating to the disease condition was seen 6 months after trans-
plantation (Chambers et al., 2014). The company Celgene is also
using placental derived cells (MSC-like) to treat Crohn’s disease
(CD) (Mayer et al., 2013) andmultiple sclerosis (MS) (Lublin et al.,
2014). Crohn’s patients treated with two injections (1 week apart)
of 2 million cells showed improved clinical response and half
were in remission 6 months after placental cell injection. At a
higher dose of 8 million cells, only one-third of patients that
were treated responded, and none were in remission after
6 months. These data indicate clinical variations in response to
cell therapy that are critically dose related. In patients with
relapsing-remitting and secondary progressive MS, the cells
were well tolerated but the treatment resulted in a variety of
minor adverse events. Data for clinical responses were variable
and generally indicated that the cells did not improve the MS
condition. It is apparent that more information is needed on the
mechanism of action of placental cells to enable better strategic
design for potential benefits to MS patients to warrant expanded
cell therapy trials.
There is interest in using cells of the amnion for clinical
improvement of lung function in preterm babies and for other
adult respiratory disorders (Murphy et al., 2014). However, these
cells cannot be expanded in vitro and there is evidence thatCell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc. 15
Figure 1. Indications Being Addressed using MSCs in Clinical Trials
Data for 352 registered clinical trials.
Figure 2. MSC Clinical Trials Classified by Clinical Phase
Data for 315 registered clinical trials.
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entiation and reparative capacity in vitro and in animal models of
pulmonary fibrosis (Lim et al., 2013). Amniotic fluid cells have
also been studied in preclinical models for a wide range of ther-
apeutic applications including repair of brain injury (Rennie et al.,
2013), but they have never progressed to first in human clinical
studies.
MSCs
Cell therapies utilizing MSCs are being explored in a large num-
ber of clinical trials. There is considerable heterogeneity in the
cells described as MSCs and a variety of sources used to isolate
and manufacture the MSC populations for clinical trials. Impor-
tant perspectives on the very different nature of the MSC popu-
lations in use clinically and their various sources have been
critically addressed recently by Bianco (2014). MSCs are classi-
cally the ‘‘postnatal, self-renewing, and multipotent stem cells
giving rise to all the skeletal tissues’’ (Bianco, 2014). They are clo-
nogenic and form stromal progeny in vitro and, when trans-
planted, form miniature organoids of bone including bone and
marrow, with host hematopoietic contributions. The stromal
cell type that is called MSC in use clinically is defined differently
from the classical MSC because they are isolated from various
tissues (including bulk cultures of bone marrow stromal cell
types) by their adhesive characteristics to plastic culture dishes
and other plastic vessels. These stromal cell types all show com-
mon expression of general fibroblastic markers and when trans-
planted, they have properties of modulating the host immune
system and other systems. These are generally transient cells
that exist briefly in the host and cannot be identified after a few
days or possibly a week or two. Their safety as allogeneic cell
transplants may be closely related to their short-term existence.
Their anti-inflammatory properties, homing to sites of damage
and inflammation, and their trophic influence on tissue repair
have made them very popular for clinical study.
In the NIH clinical trials database there are 374 registered clin-
ical trials (excluding those of unknown status) using MSCs
(Figure 1). This is a 3-fold expansion of trials over the number
noted in 2011 (Trounson et al., 2011), but the distribution of trials
by phase is much the same (Figure 2). This might suggest that
products are not moving out of the clinical pipeline. The one
phase IV study is for umbilical cord blood MSCs treating aplastic
anemia that is presently recruiting patients in China. Themajority16 Cell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc.of the MSC trials are with allogeneic cells and these trials are
happening all over the world with the highest activity in the
USA, Europe, and China. Of the phase 3 clinical trials, only three
have reported completion.
The pleiotropic properties of MSCs that include anti-
apoptosis, angiogenesis, growth factor production, neuropro-
tection, anti-fibrosis, and chemo-attraction provide a broad
spectrum for their potential in disease therapies. This includes
their properties of suppression of inflammation and their abilities
to downregulate pathogenic immune responses commonly
observed with allogeneic transplantation (Glenn andWhartenby,
2014). We have subdivided the discussion of MSC clinical trials
into conditions that utilize their immune suppression properties,
applications for regeneration in organ diseases, osteoarthritis
and related lower back pain (treatments for which primarily utilize
their anti-inflammatory properties), and repair of neurodegener-
ative disease and injury.
Immune Suppressive Properties of MSCs
MSCs and their derivatives have important roles in suppressing
activated T cell proliferation and their cytokine production. They
also increase Regulatory T cells (Tregs) that dampen killer T cell
attack on foreign cells or tissues (see the reviews of Bernardo
and Fibbe, 2013; Glenn and Whartenby, 2014). These functions
of MSCs have made them popular for studies involving contain-
ment of immune rejection in allogeneic grafting.
Systemic immunosuppression by bone marrow MSCs
(1million/kg) has been indicated in kidney allograft transplant pa-
tients for the possible improvement of rejection and fibrosis in
donor organs (Reinders et al., 2013, 2014). Graft versus host dis-
ease (GVHD) is a serious consequence of the host immune sys-
tem recognizing and rejecting allogeneic grafts. MSCs have
important immune suppressive properties that inhibit GVHD
and they have been studied in clinical trials for steroid resistant,
severe, acute GVHD disease for some time. Early phase II
studies by Le Blanc and colleagues showed that more than
50% of GVHD patients responded completely to one to five
doses of a mean of 1.4 million bone marrow MSCs (Le Blanc
et al., 2008). These complete responders had lower transplant-
related mortality than the patients with partial or no response
(37% verses 74%) and higher survival rate after 2 years (53%
verses 16%). These data were supported for stage III–IV GVHD
in children (0.4–15 years) receiving Prochymal MSCs (Prasad
et al., 2011). Complete responses were observed in 58% of
patients infused with 2–21 (mean 8) doses of 2 or 8 million
MSCs. Five of the twelve (42%) children survived for a medium
of 611 days. These studies led to registration for approval for
the use of Prochymal MSCs in steroid resistant severe pediatric
GVHD in Canada and New Zealand (Ratcliffe et al., 2013). Other
Cell Stem Cell
Reviewphase I/II studies in adults have confirmed the safety of MSC
infusion for acute and chronic GVHD with variable but improved
results for complete response and survival (Herrmann et al.,
2012; Introna et al., 2014; Kuzmina et al., 2012; Liu et al., 2011;
Muroi et al., 2013; Pe´rez-Simon et al., 2011). Data reported by
Joanna Kurtzberg in 2015 for 160 children with GVHD not
responsive to steroids who were enrolled in an expanded multi-
center access program of Mesoblast Pty Ltd. MSCs again
showed survival benefits for bone marrow transplants. Around
80% of grade B/C patients and 50% of the more severe grade
D patients survived to 100 days. Only 5%–20% of these severe
poor prognosis patients were expected to survive without MSC
therapy (Mesoblast, 2015).
While clinical benefits were shown to be very minor and not of
clinical value when MSCs were co-administered in haploidenti-
cal hematopoietic stem cell transplants for leukemia (Maziarz
et al., 2015), the Athersys Multistem MSCs have shown some
apparent benefit in reducing GVHD when used as adjunct ther-
apy for myloablative allogeneic bone marrow cell transplants
(Liu et al., 2011). However, purification of hematopoietic stem
cells and, in particular, the removal of alloreactive T cells can
probably accomplish this even more effectively (Logan et al.,
2012; Shizuru et al., 1996).
The immunosuppressive properties of MSCs have been pro-
posed as treatments for CD, despite these properties being re-
tained by CD patients’ own endogenous MSCs (Duijvestein
et al., 2010). The study showed that infusion of donor MSCs
from healthy normal patients had little effect on recipient CD pa-
rameters, as would be expected (Duijvestein et al., 2010). How-
ever, another study showed a decrease in endoscopic active
luminal CD (42%) in 7/15 patients given 2 million MSCs/kg (For-
bes et al., 2014), suggesting that there may be clinical benefits of
MSC therapy for CD. Likewise, intrathecal or intravenous injec-
tions of MSCs have been tried for advanced progressive and re-
lapsing and remitting MS, with little detectable clinical benefit
(Bonab et al., 2012; Connick et al., 2012; Llufriu et al., 2014; Yam-
out et al., 2010). There were some indications of minor reduc-
tions in MRI inflammatory parameters in the relapsing and
remitting type of MS (Llufriu et al., 2014).
Myocardial Injury Benefits of MSCs
There has been a concerted effort to demonstrate a benefit of
MSCs for cardiovascular repair, particularly a benefit to patients
with severe myocardial infarct. Generally, autologous bone
marrow cell transplants have been ineffective (Nowbar et al.,
2014). Allogeneic MSC transplants have had variable benefits
to patients with ischemic heart disease. Left ventricular ejection
fraction was improved in patients given Prochymal MSCs when
compared to placebo in a randomized, double blind, dose esca-
lation study (Hare et al., 2009). Randomized comparisons of
autologous and allogeneic MSCs (20–200 million) delivered as
transendocardial injections showed a few differences (autolo-
gous cells improved 6min walking), and only low dose allogeneic
MSCs improved left ventricular ejection fraction (Hare et al.,
2012). Furthermore, autologous MSCs appeared better than
autologous bone marrow cells when administered as transendo-
cardial injections (Bartunek et al., 2013; Heldman et al., 2014).
Intracoronary administration of MSCs has had a minor benefit
on the left ventricular ejection fraction (Lee et al., 2014b), and a
meta-analysis of all cell therapies by intracoronary administra-tion shows that there is no clinical benefit on left ventricular func-
tion (Gyo¨ngyo¨si et al., 2015). Minor benefits were observed in
weaning myocardial infarct patients from left ventricular assist
devices when compared with sham controls when the former
were treated with intramyocardial injections of 25 million of
Mesoblast’s MSCs (Ascheim et al., 2014). Genuine sustained
benefits now need to be demonstrated in phase III studies. It is
of interest to note that in at least one comparison of heart-
derived cells and MSCs, the cardiosphere cell type outper-
formed MSCs (which were bone marrow and adipose derived)
in a preclinical animal model (Li et al., 2012). The relative benefits
of the intramyocardial injection of transient allogeneic MSCs and
cultured cadaveric cardiospheres (CapricorTherapeutics, 2015)
in clinical trials will be interesting to evaluate. It is also of some
interest that scar size reduction and ventricular function occurs
in sites of MSC injection rather than non-cell injection sites (Sun-
cion et al., 2014). This suggests that the benefits of cells are
localized to sites of injection.
MSCs for Osteoarthritis and Lower Back Pain
Bone marrow MSCs would be expected to contribute to bone
and cartilage repair. In delayed bone fracture union, MSCs,
when mixed with demineralized bone and platelet-rich plasma,
halved the time to fracture union (Liebergall et al., 2013). Intra-
articular injection of MSCs in osteoarthritic patients resulted in
strong improvement in cartilage coverage and quality in the
vast majority of treated cases (Orozco et al., 2013). Clinical pa-
rameters of pain, disability, and quality of life were improved.
Likewise, patients with severe back pain due to degenerative
disc disease improved dramatically, with 71% of optimal effi-
ciency in the improvement of clinical parameters of pain and
disability, but without disc height recovery (Orozco et al.,
2011). Mesoblast has also reported the benefits of a single injec-
tion of MSCs (6 or 18 million) in a randomized, placebo-
controlled phase II study of 100 patients with chronic low back
pain due to degenerative disc disease. A single injection of 6
million MSCs gave substantial and sustained pain relief with
48% having no or minimal pain after 24 months compared with
only 13% of patients without pain who received saline control in-
jections (Mesoblast, 2015). The improvement in pain is a very
important clinical benefit for this group of patients and further
trials should confirm this benefit and hopefully improve the pro-
portion of treated pain-free cases.
MSCs for Pulmonary Disease
The use of MSCs in pediatric bronchopulmonary disorders has
been actively pursued. In preterm infants at high risk of broncho-
pulmonary dysplasia (BPD), umbilical cord blood MSCs (1 or
2 million MSCs/kg) were administered as intratracheal trans-
plants (Chang et al., 2014). Levels of inflammatory cytokines
were significantly reduced in lung aspirates 3 days after trans-
plantation and BPD severity was lower in transplant patients.
Studies in the adult have focused on acute respiratory distress
syndrome (ARDS) treated with infusions of 1, 5, or 10 million
MSCs/kg (Wilson et al., 2015). Three of nine patients had serious
adverse events, although they were not believed to be related to
cell infusion. Further studies are needed to determine benefits of
MSC therapy for these types of patients.
MSCs for Liver Disease and Diabetes
Phase I/II clinical trials of MSC therapy for liver disease have
shown some minor improvements in liver function. Liver in endCell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc. 17
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Reviewstage liver disease (cirrhosis) due to hepatitis B and C and alco-
holic and cryptogenic causes showed some response in function
as assessed by changes in creatinine, serum albumin, and bili-
rubin in response to autologous MSCs (El-Ansary et al., 2012;
Kharaziha et al., 2009). The anti-fibrotic effects of autologous
MSCs (which were 50 million MSCs administered on two occa-
sions 4weeks apart) were explored in patients with alcoholic liver
cirrhosis (Jang et al., 2014). Improvements in histological liver
biopsy samples were observed in 55% patients as well as
some change in type-1 collagen and a-smooth muscle actin.
Further studies are needed to confirm the clinical benefits of
MSCs to patients with liver disease.
Some clinical studies are underway using MSCs in patients
with type II diabetes. Data suggest some temporary change in
metabolic parameters may occur with intravenous or intra-
pancreatic endovascular injection of Wharton’s jelly (umbilical
cord) MSCs (Liu et al., 2014).
MSCs for Ischemic Stroke and ALS
MSCs are also being used in ischemic stroke patients. Fat-
derived allogeneic MSCs are being studied by intravenous injec-
tion within 2 weeks of stroke (Dı´ez-Tejedor et al., 2014). The
company Athersys is also undertaking a phase II double blind
clinical evaluation of MSCs given intravenously 24–36 hr after
stroke (Hess et al., 2014), but this was reported recently to
show no clinical benefit (FierceBiotech, 2015). It is difficult to
understand the mechanism of action of these approaches given
the transient nature and lineage differentiation properties of
MSCs. Clinical trials are also underway using MSCs for therapy
in ALS (Karussis et al., 2010; Mazzini et al., 2010, 2012). No
response to MSC injections was seen in MRI structures in the
brain or spinal cord and there were no apparent post mortem in-
dicators of beneficial change (Mazzini et al., 2010). Few clinical
benefits were reported for either intrathecal or intravenous
administration of autologous MSCs (Karussis et al., 2010; Maz-
zini et al., 2012).
Failures and Concerns for Stem Cell Clinical Trials
There have been many claims for multi- or pluri-potentiality for
cells of various origins, such as the very small cells of the
vascular system (multipotent adult progenitor cells, or MAPCs),
umbilical cord blood cells, amniotic fluid cells, and others, that
have not really converted to the broad spectrum of applications
initially envisaged. There are autologous bone marrow stem cell
trials being explored for many conditions, including stroke and
ischemic heart disease. However, in the case of the latter, benefit
has been related to factual discrepancies in the clinical data
collected, rather than the administered cell therapy (Nowbar
et al., 2014).
Clinical trial failures have been frequent for MSC therapies,
and, more recently (Bersenev, 2015), MSC trials for ulcerative
colitis and ischemic stroke (Athersys), cardiac repair (3 studies
by Miltenyi Biotec; FBC Pharmicell, Korea; and Stempeutics
Research), acute kidney injury (Allocure), ischemic stroke (Man-
ipal Acunova, India), ARDS (China), critical limb ischemia (Raval
et al., 2014), and MS (Spain) have failed or been terminated.
While clinical trial failures are to be expected in the early days
of clinical research, these disappointments are a reasonably
common feature of this first wave of cell therapy trials involving
autologous and allogeneic MSC products.18 Cell Stem Cell 17, July 2, 2015 ª2015 Elsevier Inc.While there is little scientific basis for the differentiation of
MSCs to functional neurons, there is a registered phase I/II clin-
ical trial in Russia using autologous MSC-derived neural cells
(with ‘‘a matrix scaffold as necessary’’) in 30 patients with trau-
matic spinal cord injury (Averyanov, 2014). As yet, there are no
results available for this study, which began recruitment in July
2014; there were no preclinical data provided to support this
dubious type of approach.
In contrast to the care taken to ensure the appropriate cell type
is used for transplantation by others in the field, there has been
one clinical trial reported using undifferentiated and partially
differentiated ESCs to treat cerebral palsy in children in India
under approval of an ‘‘independent ethics committee’’ and a
‘‘national apex body’’ (Shroff et al., 2014). The cells were
delivered by intravenous or intramuscular injection and a variety
of other routes. It is possible that most of the cells were
dead because of the methods used, but this is a potentially
dangerous treatment of transplanting undifferentiated pluripo-
tent stem cells that could have resulted in the formation of
teratomas in these children. These types of studies are very con-
cerning for the field.
Progress and Cautionary Notes
The progresses of stem cell clinical trials are encouraging given
that the majority are in the early phase I/II stage and in most
cases, clinical data is still being accumulated. It remains too early
to be confident that pluripotent stem cells will deliver their
considerable promise. As yet iPSCs have not received regulatory
approval to begin appearing in first in human studies, although
one patient has been treated for macular degeneration. Neural
stem cells are progressing with some interesting applications.
It is interesting that Stem Cells Inc. brain stem cells are capable
of acquiring some of the RPE cell properties such as phagocy-
tosis and secretion of neuroprotective factors. There is no evi-
dence that they make photoreceptors, but they do seem to
preserve synaptic connections between the photoreceptors
and the bipolar and horizontal cells as evidenced by the pres-
ence of synaptic ribbons in eyes receiving transplants (Cuenca
et al., 2013). The neural stem cells derive from primitive brain tis-
sue of the early fetus, which may include anterior neural plate
cells from which RPEs are derived (Graw, 2010). Studies on spi-
nal cord injury show some touch sensitivity benefit but little
motor response for neural stem cell therapies as yet. There is
also little evidence of benefit of neural stem cell therapy for
stroke patients as yet, despite well-organized consensus-based
guidelines for clinical stem cell therapies for stroke (Savitz et al.,
2011, 2014). The majority of clinical trials to date have used non-
neural cell types.
Autologous limbal stem cell expanded cultures (Holoclar) have
been recently formally approved and registered for clinical use
by the European Medicine Agency and the European Commis-
sion as the first advanced therapy medicinal product containing
stem cells (European Medicines Agency, 2015). Holoclar will be
used for moderate to severe limbal stem cell deficiency caused
by physical or chemical burns to the eye in adults. This is a major
development for global stem cell medicine. Research will
continue to explore the opportunity to establish allogeneic limbal
stem cells for effective corneal therapies from pluripotent stem
cell sources.
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ReviewAutologous endothelial stem or progenitor cells show preclin-
ical value for vascular disease and deficiency such as that seen
in critical limb ischemia. These cells in combination withMSCs or
other drug regimes may be shown to be effective as the early
clinical trials continue to evolve. Presently it is too early to
make strong predictions of their likely clinical benefits but there
are some encouraging data beginning to appear that warrant
further study.
Placental, bone marrow, and fat-derived stromal cells or
MSCs feature far and away in the largest number of clinical trials
currently underway. They have been shown to be remarkably
safe although transitory in their presence following transplanta-
tion. It has not been determined if this is due to a rapid process
of removing foreign cells or their short half-life. Since they are
immune suppressive it is likely that they are rapidly turned over
in tissues such as the lung where they generally lodge in large
numbers when administered by intravenous injection. There ap-
pears to be very little difference between autologous and alloge-
neicMSCs in their actions or clinical effects, suggesting that they
deliver a payload of cytokines that have immune-modulatory
effects and other influences on endogenous tissue regeneration.
They appear to migrate to inflammatory sites and have inflam-
matory suppressing effects that are pro-regenerative for the
affected tissue. They are rarely identified as colonizing in tissue
repair mechanisms. However, there is a general lack of knowl-
edge around their actual mechanism of action that is a handicap
for modifying clinical strategies to improve their actions (see
discussion of ‘‘Roadblocks to translation of stem cell therapies’’
in Dimmeler et al., 2014). Nevertheless, clinical benefits have
been observed in many early clinical trials that have attracted
continued funding for larger-scale efficacy studies. The contribu-
tions of bone marrow MSCs to bone and cartilage repair and
reduction of osteoarthritic and lower back pain are impressive.
Likewise, their use for controlling GVHD, particularly in children,
is important for cancer and transplantation medicine. Whether
MSCs from sources other than bone marrow can also show
these clinical benefits is less certain. Notably the Janssen Com-
pany hasMSC-like umbilical cord tissue cells in early clinical trial
for macular degeneration but there are no clinical data available
as yet. It is also too early to decide if placental stem cells,
whether stromal or otherwise (such as amniocytes) have a future
significant role in clinical medicine. Clearly the research will
continue to probe these opportunities.
Some of the failures in clinical trials may be predicted on the
basis that there was insufficient scientific data to support a
strong clinical benefit (Dimmeler et al., 2014). In other cases,
there is insufficient clinical benefit apparent in early efficacy
studies to warrant further commitment of relatively scarce
finances. It is critically necessary to show clear and significant
clinical benefit in phase II studies because the heterogeneity of
human disease in more extensive phase III or IV studies will often
erode the significance of minor benefits apparent in early trials.
The new regulatory pathway established in Japan (Konomi
et al., 2015), where products may enter the marketplace with
provisional approval if phase II studies show efficacy, will test
the robustness of the entire global regulatory systems. If prod-
ucts become available without testing for sufficient benefit
then patients will not be served well by the evolving cell thera-
pies. If the need for regulated phase III studies can be dispensedwith, many more products may become available in a shorter
timeframe and more cost-effective manner. The present Review
shows that cell therapies are rapidly evolving but few at present
would have demonstrated sufficient clinical benefit to warrant
their adoption as useful therapies in an abbreviated regulatory
system. As studies with stronger scientific evidence of likely clin-
ical benefit and demonstratedmechanisms of action evolve from
preclinical trials, it might be expected that the conversion to
registered stem cell therapies will increase strongly with time.
We are optimistic from the present Review that there will be
many stem cell products that will meet the criteria for registered
products in the established regulatory systems over the next
5 years.ACKNOWLEDGMENTS
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